The list features the top 50 biopharma companies by 2018 prescription
sales
CRANBURY, N.J.–(BUSINESS WIRE)–#pharma—Pharmaceutical Executive, a multimedia platform for industry
leaders to exchange experiences and insights about innovative business
and marketing ideas, has released its annual Pharma50 list for 2019. Now
in its 19th year, the list reveals that companies are now focusing on
diversification, big brand expansions and positioning a new wave of
products.
“With all the different dynamics at play, the importance of having
strong and stable leadership has perhaps never been more critical for
biopharma,” said Tom Ehardt, president of MultiMedia Healthcare, LLC. “Pharmaceutical
Executive’s Pharma50 list provides an insightful look into the sales
performance of these companies and how they are achieving those goals.”
The results show Pfizer in the top spot for the fourth straight year.
Through data provided in partnership with life sciences market
intelligence firm Evaluate Ltd, Pfizer’s 2018 prescription drug revenue
totaled $45.3 billion. Pfizer’s sales of breast cancer drug Ibrance
spiked 31.7% last year from 2017 full-year figures.
Coming in second and third are Roche and Novartis, respectively, with
Roche inching past Novartis with an increase of 6.8% in prescription
drug sales. Roche also spent more than any company on research and
development: $9.8 billion.
To view a complete list of the Pharma50, click here.
About Pharmaceutical Executive
Pharmaceutical Executive is a multimedia platform that offers
news, opinions, analysis, features and executive profiles. This digital
resource serves as a forum for industry leaders to exchange opinions,
experiences and insights about innovative business and marketing ideas,
strategies and tactics. Pharmaceutical Executive is part of
MultiMedia Healthcare, LLC.
Contacts
Pharmaceutical Executive Media
Theresa Burek /
609-250-4331
tburek@mjhassoc.com
Michelle Wood / 609-716-7777
mwood@mmhgroup.com